This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
5 Citations 17 Q&As
4 Citations 17 Q&As
3 Citations 15 Q&As
Facts about Solute carrier family 2, facilitated glucose transporter member 1.
Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses. .
Human | |
---|---|
Gene Name: | SLC2A1 |
Uniprot: | P11166 |
Entrez: | 6513 |
Belongs to: |
---|
major facilitator superfamily |
DYT17; DYT18; DYT18DYT17; DYT9; EIG12; Glucose transporter type 1, erythrocyte/brain; Glut1; GLUT-1; GLUT1DS; GLUT1GLUT; HepG2 glucose transporter; MGC141895; MGC141896; PED; SLC2A1; solute carrier family 2 (facilitated glucose transporter), member 1; solute carrier family 2, facilitated glucose transporter member 1
Mass (kDA):
54.084 kDA
Human | |
---|---|
Location: | 1p34.2 |
Sequence: | 1; NC_000001.11 (42925353..42958868, complement) |
Detected in erythrocytes (at protein level). Expressed at variable levels in many human tissues.
Cell membrane; Multi-pass membrane protein. Melanosome. Localizes primarily at the cell surface (PubMed:18245775, PubMed:19449892, PubMed:23219802, PubMed:25982116, PubMed:24847886). Identified by mass spectrometry in melanosome fractions from stage I to stage IV (PubMed:17081065).
The marker SLC2A1 has many uses and benefits. These are discussed in this article including availability, specific applications, Validation, and Benefits. We will also discuss the drawbacks and advantages of the marker SLC2A1. Find out more here! This article will provide an overview of the purposes and benefits of SLC2A1 markers and provide information on how you can obtain them.
SLC2A1 is a gene that produces glucose transporter type 1 (GLUT1) It is a protein that is located in the cell's outer membrane. The protein transports glucose into cells, which will later be used to fuel the cells. There are many benefits to the SLC2A1 genetic. For instance, it offers a quick and simple way to detect glucose levels in the blood.
It has been shown that SLC2A1-AS1 gene expression is an independent predictor for HCC recurrence-free survival. SLC2A1 gene expression was associated with a greater chance of survival after HCC recurrences. This makes it an extremely useful biomarker to detect those suffering from this disease and track their progress.
Although there are only some studies, a new study has revealed that SLC2A1 and AS1 expression is positively linked to GLUT1 expression. The association between SLC2A1-AS1 and GLUT1 expression is significant and suggests that SLC2A1 may be important for detecting the occurrence of cancer. SLC2A1A1A1A1 is also associated with an increase in the size of tumors.
This study is the first to provide evidence that the SLC2A1 gene is a reliable indicator of prostate cancer. It was discovered that SLC2A1 expression is higher in the CRC tissues than in normal tissues. The study also revealed that the gene is more common in prostate cancers such as adenocarcinoma. However further validation is required to determine if SLC2A1 can be a reliable marker for prostate cancer.
The SLC2A1 gene was identified as a biomarker of CRC after studies that linked it to immune infiltration, m6A modifications and ferroptosis. The findings suggest that SLC2A1 is linked with m6A modification in CRC and may affect the progression of the disease. The ceRNA regulatory network is associated with the SLC2A1 genes.
The SLC2A1 gene was associated with the expression of 25 genes related to ferroptosis. The SLC2A1 marker was connected to the expression of FDFT1, GPX4, RPL8, CS. It also had a good correlation with the HSPB1G gene and MT1G which are the other genes involved in ferroptosis. Therefore, SLC2A1 is an attractive candidate for cancer diagnosis.
Genes that are related to SLC2A1 are enhanced in basic cell functions. These genes are also closely linked to the nucleus as well as other functions of the cell, such as cell cycle, organelles and cell cycles, as well as metabolic processes. Their expression has been linked to lung diseases and tumor recurrence. These results suggest that the SLC2A1 genes are a good candidate gene for prostate carcinoma screening.
The expression of the SLC2A1 gene was highly associated with the prognosis of LUAD patients. The gene is closely related to the immune system within the cancer. This gene could be used to develop immunotherapy treatments for this disease. If confirmed, it may be used to aid in clinical prognosis. This study is among the few that has been approved by the National Cancer Institute.
The immune infiltration of tumors has been found to be linked to the presence of activated CD4+ memory cells and mast cells. These immune cells are believed to play an important role in the immune microenvironment of tumors. It is possible that the SLC2A1 marker regulates the infiltrating immune cells of tumors. Therefore, it is important to detect the presence of SLC2A1 in tumor immunotherapy.
The SLC2A1 gene is found in various tissues and organs is a known marker for neural stem cells. It is found in human brain pericytes, and in some instances, in other tissues. Even though the protein is found in a tiny fraction of pericytes, it is a useful indicator of neural stem cells in mouse and human. This gene has many applications.
Patients suffering from epilepsy or movement disorders are to be considered if they have low levels of cerebrospinal fluid. To rule out any other genetic diseases, genetic tests should be conducted. In the event of delay, it can cause neurological degeneration as well as ineffective treatments. Because of this, early diagnosis is crucial. Specific applications of the SLC2A1 marker in epilepsy and movement disorders might be beneficial to those who suffer from this gene mutation.
In a recent study, researchers discovered the existence of the SLC2A1 gene marker in humans cancers. They found that SLC2A1 expression levels in a cohort of 15 different types of cancer were significantly higher than the levels of normal tissue. Other research also supports that the SLC2A1 gene marker in humans cancers. Here are some of the reasons why the gene marker might be beneficial in clinical trials.
SLC2A1 has been linked to colorectal carcinoma. According to the Kyoto Encyclopedia of Genes and Genomes (Kyoto Encyclopedia of Genes and Genomes) SLC2A1 is associated with colorectal cancer. Despite this however, the precise location of the gene remains to be identified. Genetic testing is the only way to know if the SLC2A1 genes are present in a particular cancer cell.
SLC2A1 can also be used to predict the outcome of CRC. It is also associated to immune infiltration, m6A modification ferroptosis, as well as the ceRNA regulatory system. However, very only a few studies have investigated the synthesis of SLC2A1 within CRC. The researchers also note that SLC2A1 is linked to cancer cell proliferation.
The SLC2A1 gene has been expressed in TCGA CRC specimens. The SLC2A1 genes were associated with 25 ferroptosis-related gene genes in CRC. FDFT1, GPX4, RPL8 SLC1A5 and RPL8 were among the genes associated with SLC2A1. It also showed positive correlations with AIFM2, HSPB1, as well as MT1G.
In addition, SLC2A1 can be found in a number of tumors, including CRC. The ROC curve revealed that the expression of SLC2A1 in CRC was correlated with the time between progression-free intervals and the stage of tumor. The genes related to it were implicated in multiple biological processes. In humans, the expression of SLC2A1's mRNA was positively linked to ferroptoses, neutrophils, and the modification of m6A.
SLC2A1 is a glycolysis protein. This gene may be overexpressed to speed up the growth and progression of CRC. Further research into the biological effects and implications of SLC2A1 might help improve the diagnosis and treatment of CRC. There are many other genes in the blood which could play a role on the development of CRC. This is the reason why the availability of SLC2A1 gene markers has been an important source of controversy.
PMID: 3839598 by Mueckler M., et al. Sequence and structure of a human glucose transporter.
PMID: 2834252 by Fukumoto H., et al. Characterization and expression of human HepG2/erythrocyte glucose- transporter gene.
*More publications can be found for each product on its corresponding product page